The companies are looking to get Moventig approved for the treatment of opioid-induced constipation (:OIC) in adults whose response to laxatives has been inadequate. Nektar has a worldwide license ...

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® ...

Patients in England and Wales with opioid-induced constipation will now be able to get treatment with AstraZeneca’s Moventig on the National Health Service following the drug’s launch this week.

AstraZeneca’s naloxegol for opioid-induced constipation has been approved in the EU as Moventig, a few weeks after getting the go-ahead in the US. Moventig is the first once-daily peripherally-acting ...

First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives AstraZeneca today announced that MOVENTIG® (naloxegol) has been ...

First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives AstraZeneca today announced that MOVENTIG® (naloxegol) has been ...

Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of ...

AstraZeneca said today it has agreed to sell rights to its marketed opioid-induced constipation treatment, marketed as MOVENTIG (naloxegol) in the EU and four European nations, to a subsidiary of ...

MONTREAL, QUEBEC--(Marketwired - Dec 15, 2016) - Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company today announced the signing of an exclusive license ...

LONDON (Reuters) - A drug for the treatment of opioid-induced constipation, MOVENTIG, from AstraZeneca, was recommended for approval by European regulators on Friday. Recommendations for marketing ...

AstraZeneca has sold ProStrakan European rights to its opioid-induced constipation (OIC) drug Moventig for an upfront fee of $70 million plus other payments and royalties. AstraZeneca has sold ...

Nektar Therapeutics ( NKTR) and AstraZeneca's ( AZN) Moventig is one step closer to receiving EU approval after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...